High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae .

Autor:	Stazzoni S; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy., Troisi M; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy., Abbiento V; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Sala C; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy., Andreano E; Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy., Rappuoli R; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.; Fondazione Biotecnopolo di Siena, Siena, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in microbiology [Front Microbiol] 2023 Aug 16; Vol. 14, pp. 1243427. Date of Electronic Publication: 2023 Aug 16 (Print Publication: 2023).
DOI:	10.3389/fmicb.2023.1243427
Abstrakt:	Neisseria gonorrhoeae (gonococcus) is an obligate human pathogen and the etiological agent of the sexually transmitted disease gonorrhea. The rapid rise in gonococcal resistance to all currently available antimicrobials has become a significant public health burden and the need to develop novel therapeutic and prophylactic tools is now a global priority. While high-throughput screening methods allowed rapid discovery of extremely potent monoclonal antibodies (mAbs) against viral pathogens, the field of bacteriology suffers from the lack of assays that allow efficient screening of large panels of samples. To address this point, we developed luminescence-based (L-ABA) and resazurin-based (R-ABA) antibody bactericidal assays that measure N. gonorrhoeae metabolic activity as a proxy of bacterial viability. Both L-ABA and R-ABA are applicable on the large scale for the rapid identification of bactericidal antibodies and were validated by conventional methods. Implementation of these approaches will be instrumental to the development of new medications and vaccines against N. gonorrhoeae and other bacterial pathogens to support the fight against antimicrobial resistance. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Stazzoni, Troisi, Abbiento, Sala, Andreano and Rappuoli.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu